Characteristics of Primary and Plasmatic Hemostasis in Preeclampsia - a Cross-sectional Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coagulation Disorder, Blood
- Sponsor
- Goethe University
- Enrollment
- 60
- Primary Endpoint
- Area under the aggregation curve in the ADPtest of the Multiple Electrode Aggregometry
- Last Updated
- 8 years ago
Overview
Brief Summary
The study aims to investigate the impact of preeclampsia on hemostasis.
Detailed Description
In comparison to healthy pregnant women and non-pregnant woman, this study analyses parameters of primary hemostasis and plasmatic coaguation in preeclamptic pregnant woman. Detailed analyses of the platelet function is performed using the Multiple Electrode Aggregometry, detailed analyses of the plasmatic coagulation syste is performed by isolated coaguation factor analyses and conventional coagulation analyses.
Investigators
Christian F. Weber, MD
Prof. Dr. med. Christian F. Weber
Cooperative Weichteilsarkom Study Group
Eligibility Criteria
Inclusion Criteria
- •Platelet count \> 100 / nll
- •In study group and control group 1: Week of Pregnancy: 35-40
- •in control group 2: healthy, not pregnant woman
Exclusion Criteria
- •Hereditary coagulopathy
- •Missing content of the patient / proband
- •Eclampsia
- •HELLP syndrome
- •CRP \> 1 mg/dl
- •Fever (\> 38°C)
Outcomes
Primary Outcomes
Area under the aggregation curve in the ADPtest of the Multiple Electrode Aggregometry
Time Frame: Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study
ADP induced platelet aggregation
Secondary Outcomes
- Area under the aggregation curve in the ASPItest of the Multiple Electrode Aggregometry(Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study)
- Area under the aggregation curve in the TRAPtest of the Multiple Electrode Aggregometry(Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study)
- Parameters of plasmatic coagulation system(Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study)